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Atherosclerosis, the underlying cause of heart attacks and strokes, is a chronic inflamma-
tory disease of the artery wall. Immune cells, including lymphocytes modulate atheroscle-
rotic lesion development through interconnected mechanisms. Elegant studies over the
past decades have begun to unravel a role for B cells in atherosclerosis. Recent findings
provide evidence that B cell effects on atherosclerosis may be subset-dependent. B-1a B
cells have been reported to protect from atherosclerosis by secretion of natural IgM anti-
bodies. Conventional B-2 B cells can promote atherosclerosis through less clearly defined
mechanism that may involve CD4 T cells. Yet, there may be other populations of B cells
within these subsets with different phenotypes altering their impact on atherosclerosis.
Additionally, the role of B cell subsets in atherosclerosis may depend on their environmen-
tal niche and/or the stage of atherogenesis. This review will highlight key findings in the
evolving field of B cells and atherosclerosis and touch on the potential and importance of
translating these findings to human disease.
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INTRODUCTION
Atherosclerosis and its attendant sequelae of heart attacks and
strokes remains a leading cause of death and disability in West-
ernized countries (Roger et al., 2012). Substantial work over the
last several decades has clearly established atherosclerosis as a
chronic inflammatory disease of the blood vessel wall (Figure 1).
Immune cells including macrophages, dendritic cells, mast cells,
neutrophils, T cells, and B cells regulate the atherogenic process
(Libby,2002,2012; Hansson and Hermansson,2011; Lahoute et al.,
2011). As such, immunomodulatory therapy holds promise as
the next frontier for improving prevention of atherosclerotic car-
diovascular disease (Keaney, 2011; Libby et al., 2011; Weber and
Noels, 2011). Deposition of lipids such as low-density lipopro-
tein (LDL) in the subendothelial space of the intima and other
injurious stimuli have been implicated as initial inflammatory
triggers (Lusis, 2000). Vessel wall enzymes can act on deposited
lipids to generate modifications in the lipids, such as oxidation,
that serve both directly and indirectly as inflammatory signals
(Hansson et al., 2006; Chou et al., 2008; Steinberg and Witztum,
2010; Miller et al., 2011). Inflammatory cells are then recruited to
the arterial wall, promoting progression of plaques through a host
of interconnected mechanisms (Weber et al., 2008; Galkina and
Ley, 2009; Tabas, 2010; Hansson and Hermansson, 2011; Murray
and Wynn, 2011). For example, recruited monocytes differentiate
into macrophages within the plaque. There they engulf oxidized
lipids, becoming foam cells, which secrete chemokines and other
cytokines that further promote immune cell infiltration and acti-
vation. In addition, many of these lipid-laden macrophages subse-
quently undergo apoptosis and necrosis, dumping their contents
into the extracellular space, creating a necrotic core (Figure 1).
Formation of the necrotic core promotes plaque expansion and,
if not contained, can lead to the unstable syndromes that result in
heart attack and stroke. In addition to immune cell entry into the
plaque via the blood vessel lumen, immune cells are also found
in the adventitia, or outer layer of the vessel wall. In fact, aortic
tertiary lymphoid organs (ATLOs) have been identified in the aor-
tic adventitia of aged mice at sites of advanced intimal plaque.
Conduit networks, similar to those that filter soluble substances
within lymph nodes (Sixt et al., 2005) and facilitate lymphocyte
organization in the white pulp of the spleen (Nolte et al., 2003)
connect the adventitia with the vessel wall (Figure 1). The role
of the adventitia in regulating atherosclerosis has been reviewed
elsewhere (Campbell et al., 2012; Weih et al., 2012).
Lymphocytes have long been identified in the adventitia and
plaque of diseased arteries. In his 1915 book, Diseases of the
Arteries, Including Angina Pectoris, Sir Thomas Clifford Allbutt
noted that,“Round cell growth in the adventitia in arteriosclerosis
is correlated with absorption of depraved matter from the dis-
eased intima” (Allbutt, 1915), suggesting that lymphocytes might
serve to protect against the accumulation of lipids and necrotic
material in blood vessel walls. Subsequent histological studies
confirmed the presence of lymphocytes in diseased blood vessels,
underscoring the hypothesis that lymphocytes may be important
regulators of atheroma development (Gerlis, 1956; Schwartz and
Mitchell, 1962). Yet, it was not until the advent of immunohis-
tological reagents in the 1980s which allowed the visualization of
specific types of lymphocytes that the presence of B cells in ath-
erosclerotic plaques and the adventitia of diseased blood vessels
was clearly confirmed (Parums et al., 1990; Zhou and Hansson,
1999; Houtkamp et al., 2001). A wealth of active and passive
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FIGURE 1 | Characteristics of advanced atherosclerotic disease. As
luminal LDL is deposited into the subendothelial space of the blood vessel
wall, it becomes oxidized. Oxidized lipids trigger the recruitment of
leukocytes to the subendothelial space. Monocytes differentiate into
dendritic cells or tissue macrophages that take up oxidized lipids and
become foam cells. Without effective clearance of these apoptotic-prone
cells, they accumulate, secrete pro-inflammatory cytokines and undergo
apoptosis and necrosis, dumping their lipid contents into the extracellular
space to create a necrotic core. Cytokines and immunoglobulins produced
by vessel wall and immune cells can further modulate atherosclerosis.
ATLOs are found in the adventitia of diseased vessels and are composed of
T cells, B cells, macrophages, and other leukocytes. Soluble factors can
cross into the media through conduits and may contribute to plaque
development. Abbreviation: oxLDL, oxidized LDL; ATLO, aortic tertiary
lymphoid organ; EC, endothelial cell; SMC, smooth muscle cell; Adip,
adipocyte; Mono, monocyte; Mac, macrophage; FC, foam cell; DC,
dendritic cell.
immunization studies in mice and the identification of athero-
protective IgM antibodies, implicated B cells in attenuating ather-
osclerosis (Palinski et al., 1995; Ameli et al., 1996; Freigang et al.,
1998; Nicoletti et al., 1998; Zhou et al., 2001; Binder et al., 2003,
2004; Faria-Neto et al., 2006). As new findings on the role of B cells
in atherosclerosis have recently emerged, and in keeping with the
theme of this series, this review will focus on the role of B cells in
atherosclerosis.
B CELLS IN ATHEROSCLEROSIS
Two groups in 2002 directly tested the hypothesis that B cells mod-
ulate atherosclerosis. Caligiuri et al. reported that splenectomy
of the atherogenic apolipoprotein-E knockout (Apoe−/−) mouse
exacerbated atherosclerosis compared to the sham operated con-
trol mouse. Adoptive transfer of splenic B cells from atherosclerotic
Apoe−/− mice not only rescued these mice from the athero-
genic effects of splenectomy, but also reduced atherosclerosis to
significantly less than that observed in the non-splenectomized
controls. In addition, adoptive transfer of B cells, but not T cells,
from atherosclerotic Apoe−/− mice to non-splenectomized, sham
operated mice significantly attenuated atherosclerosis (Caligiuri
et al., 2002). Consistent with these findings, Major et al. reported
increased atherosclerosis in atherogenic LDL receptor knock-
out (Ldlr−/−) mice transplanted with bone marrow from B cell
deficient (µMT ) mice compared to Ldlr−/− mice transplanted
with bone marrow from C57BL/6 mice (Major et al., 2002). More
recent studies confirmed a protective role for B cells in atheroscle-
rosis. Lewis et al. demonstrated that Ldlr−/−mice unable to secrete
IgM (sIgM ) had accelerated atherosclerosis compared to control
Ldlr−/− mice when fed a Western diet (Lewis et al., 2009). Doran
et al. demonstrated marked attenuation of Western diet-induced
atherosclerosis in B cell deficient µMT Apoe−/− mice with the
adoptive transfer of splenic B cells from Apoe−/− mice (Doran
et al., 2012). Taken together, these studies indicate that B cells
protect from Western diet-induced atherosclerosis.
In contrast, in 2010 two groups utilized an anti-CD20 mon-
oclonal antibody to deplete B cells in Apoe−/− mice and found
attenuation of Western diet-induced atherosclerosis (Ait-Oufella
et al., 2010; Kyaw et al., 2010). Confirmation of an atherogenic role
for B cells was provided by these same two groups in studies using
atherosclerosis-prone mice null for B cell activation factor recep-
tor (Baffr−/−) (Kyaw et al., 2012; Sage et al., 2012). Baffr−/− mice
lack B-2 B cells that require BAFF for survival, such as follicular or
marginal zone B cells (Mackay and Browning, 2002; Sasaki et al.,
2004). Baffr−/− Apoe−/−mice developed less severe atherosclerosis
compared to control Apoe−/− mice when fed an atherogenic diet
(Kyaw et al., 2012). Additionally, Ldlr−/− mice reconstituted with
bone marrow from Baffr−/− mice had less Western diet-induced
atherosclerosis compared to Ldlr−/−mice reconstituted with bone
marrow from C57BL/6 mice (Sage et al., 2012). These studies sug-
gest that B cells can aggravate atherosclerosis development. The
apparent discrepancy in findings between studies suggesting an
atheroprotective role for B cells and those suggesting an athero-
genic role for B cells may be explained by unique roles for specific
B cell subsets in regulating atherosclerosis. Indeed, anti-CD20
monoclonal antibody treatment and deletion at the Baffr locus
predominantly depleted B-2 cells but not B-1a B cells (Mackay
and Browning, 2002; Sasaki et al., 2004; Hamaguchi et al., 2005;
Ait-Oufella et al., 2010; Kyaw et al., 2010, 2012; Sage et al., 2012).
Below we briefly describe B cell subsets, followed by known and
putative roles of these B cell subsets in atherosclerosis (Figure 2).
B CELL SUBSETS
B cells can be divided into two developmentally distinct lineages,
B-1 and B-2. These lineages arise in overlapping waves within a lay-
ered immune system where B-1 B cell development predominates
in the fetus and B-2 B cell development in the adult. B-2 B cells
include follicular B cells and marginal zone B cells; and B-1 B cells
include B-1a B and B-1b B cells (Kantor and Herzenberg, 1993;
Rothstein, 2002; Herzenberg and Tung, 2006; Baumgarth, 2011;
Montecino-Rodriguez and Dorshkind, 2012). Common surface
markers used to identify these B cell subsets are outlined in Table 1.
Conventional follicular B-2 B cells undergo isotype switching and
affinity maturation in the spleen and lymph nodes in response to
T-dependent antigens to either become plasma cells that secrete
large amounts of antibody, or memory B cells with the ability to
produce specific antibodies upon re-exposure to the same antigen
(Rajewsky, 1996; Tarlinton, 2006; Allen et al., 2007; Fairfax et al.,
2008). Unlike conventional follicular B-2 B cells of the adaptive
immune system, marginal zone B cells are considered part of the
innate immune system. Marginal zone B cells reside in the spleen
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FIGURE 2 | Known and putative roles for B cell subsets in
atherosclerosis. Conventional, follicular B-2 B cells may promote
atherosclerosis by skewing CD4 T cell differentiation to IFNγ producing Th1
cells and away from IL-17 producing Th17 T cells. The role of Bregs in
atherosclerosis is not yet determined, but they may attenuate atherosclerosis
by secretion of IL-10. Peritoneal B-1a B cells attenuate atherosclerosis through
production of IgM, and potentially IL-10. PD-L2 is expressed on anti-PC B-1a B
cells, potentially marking atheroprotective cells within this subset. The role of
innate response activator B cells (IRA; derived from peritoneal B-1a B cells) in
atherosclerosis is unknown but they produce GM-CSF, which may be linked to
atherogenesis. The role of B-1b B cells in atherosclerosis is unknown. *(- - -)
Role in atherosclerosis not yet reported.
Table 1 | B cell subset markers.
Subset Surface markers* Citation
Follicular CD19+ B220+ IgMdull IgDhi
CD21mid CD23+
Pillai and Cariappa
(2009)
Marginal zone CD19+ B220+ IgMhi IgDdull
CD1dhi CD21hi CD23−
Pillai and Cariappa
(2009)
B-1a CD19+ B220low/mid IgMhi
IgDdull CD43+ CD11b+ CD5+
Hardy and Hayakawa
(2001)
B-1b CD19+ B220low/mid IgMhi
IgDdull CD43+ CD11b+ CD5−
Hardy and Hayakawa
(2001)
*Surface markers define follicular and marginal zone B cells in the spleen, and
B-1 cells in the peritoneal cavity.
and are positioned to immediately respond to antigens in the blood
that are filtering through the spleen (Martin and Kearney, 2002;
Pillai et al., 2005).
Mature, adult B-1 B cells develop from fetal tissues includ-
ing the liver and bone marrow, and less so from progenitors in
the adult spleen and bone marrow (Montecino-Rodriguez et al.,
2006; Esplin et al., 2009; Holodick et al., 2009; Barber et al., 2011;
Ghosn et al., 2011; Montecino-Rodriguez and Dorshkind, 2012).
Mature B-1 B cells are primarily found in serosal cavities and the
spleen and have the capacity to self-renew. B-1 B cells are largely T
cell-independent and produce the majority of IgM antibodies that
recognize self and foreign antigens (Tumang et al., 2004; Hardy,
2006; Baumgarth, 2011). B-1a B cells spontaneously produce nat-
ural IgM antibodies, which constitutes most of the serum IgM at
homeostasis (Forster et al., 1991; Mond et al., 1995a,b; Baumgarth
et al., 1999; Ehrenstein and Notley, 2010). Additionally, their anti-
body repertoire is biased toward self-reactivity (Hardy et al., 1989;
Mercolino et al., 1989; Pennell et al., 1989; Wang and Clarke, 2004;
Rowley et al., 2007). B-1b B cells have a distinct role from B-1a
B cells in that they can be induced to secrete antibodies by cross-
linking the BCR on antigen specific cells. This response includes
producing IgM or isotype switching to IgG3 or IgA,and may lead to
unconventional memory formation (Hsu et al., 2006; Obukhanych
and Nussenzweig,2006;Alugupalli, 2008; Foote and Kearney,2009;
Haas, 2011).
Regulatory B cells (Bregs) are defined by their ability to inhibit
autoimmune pathogenesis and restore tissue homeostasis mainly
through production of IL-10 (Bouaziz et al., 2008; Lund and Ran-
dall, 2010; Mauri and Blair, 2010; Klinker and Lundy, 2012; Mauri
and Bosma, 2012). Varying proportions of IL-10-producing B
cells are found in several B cell subsets such as transitional 2-MZ
precursor cells, MZ cells, and B-1a B cells, making it difficult to
define a particular set of surface markers for Bregs. At present, the
lack of clarity with respect to surface immunophenotype makes
understanding Breg development challenging (Mauri and Bosma,
2012).
B-1a B CELLS IN ATHEROSCLEROSIS
Kyaw et al. recently confirmed the hypothesis that B-1a B cells
can protect from atherosclerosis. Consistent with previous data,
they demonstrated that splenectomized mice contain fewer B-1a
B cells (Wardemann et al., 2002) and increased atherosclerosis
(Caligiuri et al., 2002). Adoptive transfer of B-1a B cells attenu-
ated splenectomy-aggravated atherosclerosis. B-1a B cells produce
IgM antibodies that have long been implicated in atheroprotec-
tion (Binder et al., 2005). Indeed, adoptive transfer of B-1a B
cells from sIgM mice did not protect from splenectomy-aggravated
atherosclerosis (Kyaw et al., 2011).
The mechanisms whereby B-1a B cell-derived IgM can protect
from atherosclerosis have been best characterized using the pro-
totypic monoclonal IgM antibody, E06 (Chang et al., 1999, 2004;
Hörkkö et al., 1999; Shaw et al., 2000; Binder et al., 2003; Chou
et al., 2009). E06 is considered a natural antibody because it is
structurally and functionally similar to the classic antibody T15,
and is produced by B-1a B cells at homeostasis in germ-free mice
(Shaw et al., 2000; Chou et al., 2009). It was cloned from spleens
of Western diet fed Apoe−/− mice and is able to bind oxidized
LDL (oxLDL) in serum and in atherosclerotic lesions (Palinski
et al., 1996). E06 inhibits uptake of oxLDL by macrophages (Bird
et al., 1999; Hörkkö et al., 1999), preventing foam cell formation,
inhibiting release of pro-inflammatory cytokines in the athero-
sclerotic lesion. Additionally, E06 binds to epitopes on membrane
phospholipids of pro-inflammatory apoptotic cells and mediates
apoptotic cell clearance (Chen et al., 2009; Chou et al., 2009). Effec-
tive clearance of apoptotic cells and oxLDL neutralization reduces
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pro-inflammatory effects on other vessel wall cells (Chang et al.,
1999, 2004; Huber et al., 2002; Binder et al., 2005; Tabas, 2010).
Natural IgM antibodies, typified by E06, provide one mechanism
whereby B-1a B cells can attenuate atherosclerotic plaque progres-
sion. This important class of antibodies and their role in innate
immunity and atherosclerosis are reviewed in detail by Grönwall
et al. (2012) in this series.
Characterization of the impact of splenectomy and B-1a B
rescue on atherosclerotic plaques provided in vivo support for
atheroprotective mechanisms originally described in vitro (Binder
et al., 2005; Kyaw et al., 2011; Miller et al., 2011; Grönwall et al.,
2012). Splenectomy led to reduced atherosclerotic lesion IgM con-
tent and increased the size of the necrotic core within the lesion
(Kyaw et al., 2011). Large lesional necrotic cores typify advanced
unstable plaques and are linked to failed apoptotic cell clearance
(Seimon and Tabas, 2009; Tabas, 2010). Consistent with previ-
ous work demonstrating increased IgM in atherosclerotic lesions
of Rag−/− mice after adoptive transfer of B-1 cells (Chou et al.,
2009), adoptive transfer of B-1a B cells to splenectomized mice
increased lesional IgM. The increased IgM was associated with a
reduced necrotic core, an effect that was lost when the transferred
B-1a B cells came from sIgM null mice (Kyaw et al., 2011). These
data suggest that the increased necrotic core could be due to failed
IgM-mediated clearance of apoptotic foam cells. Indeed, adop-
tive transfer of B-1a B cells reduced splenectomy-induced lesional
apoptosis. However, it is not clear that this effect was dependent on
IgM, as there was a trend toward an increase in apoptotic cells in
lesions from mice receiving B-1a B cells null for sIgM compared to
wildtype, but it was not statistically significant (Kyaw et al., 2011).
Consistent with this observation, sIgM Ldlr−/− mice had only a
non-significant trend toward an increase in lesion apoptotic cell
content compared to control Ldlr−/− mice (Lewis et al., 2009).
Additional studies will be needed to fully address the role of B-
1a B cell-derived IgM in apoptotic clearance in vivo. Moreover,
IgM-dependent effects of B-1a B cells may need to be tested in a
model without splenectomy as B-1a B cells may need the spleen
for full IgM production. B-1a B cells in the peritoneal cavity spon-
taneously secrete low amounts of IgM, but in the spleen, they are
“super-secretors”(Holodick et al., 2010), suggesting that the spleen
may be important for B-1a B cells to produce large amounts of
IgM antibodies against modified lipids that are protective against
atherogenesis. In addition, these results raise the possibility that
B-1a B cells may also regulate apoptotic cell clearance by mech-
anisms independent of IgM. B-1a B cells are known to produce
cytokines involved in atheroprotection (O’Garra et al., 1992) and
future studies are needed to determine if production of cytokines
might be another mechanism whereby B-1a B cells protect from
atherosclerosis (Figure 2).
Many other questions about the role of B-1a B cells in ather-
osclerosis remain. IgM that recognizes apoptotic cells and oxLDL
are the most well studied natural antibodies, but are there other
protective antibodies that regulate atherosclerosis? Are there harm-
ful autoreactive antibodies that have pro-atherogenic effects? Are
there specific subtypes of B-1a B cells that have atheroprotective
functions? Programmed death-1 ligand 2 (PD-L2), a ligand for
PD-1, is expressed on 50–70% of B-1a B cells. The PD-L2 posi-
tive B-1a B population has a biased immunoglobulin repertoire for
self-reactivity, can present antigen more potently, induce Th17 for-
mation, and can switch isotype more readily than PD-L2 negative
B-1a B cells (Figure 2) (Zhong et al., 2007a,b; Zhong and Rothstein,
2011; Wang and Rothstein, 2012). Might PD-L2 mark an athero-
protective population within the B-1a B cell subset? Additionally,
do B-1a B cells function locally in the aorta? Are there functionally
relevant numbers of B-1a B cells in the adventitia or surrounding
peri-aortic adipose tissue? Do they have different roles at home-
ostasis and early disease compared to late disease? B-1b B cells also
produce IgM and can undergo clonal expansion in response to
foreign antigen (Viau and Zouali, 2005; Hardy, 2006; Baumgarth,
2011). Yet, do B-1b B cells act in atherosclerosis (Figure 2)?
B-2 B CELLS IN ATHEROSCLEROSIS
B cell depletion studies have suggested that B-2 B cells are an
atherogenic B cell subset. In support of this finding, adoptive
transfer of 5× 106 splenic B-2 cells from a C57BL/6 background,
aggravated atherosclerosis in B cell deficient µMT Apoe−/− mice
fed 6 weeks of Western diet (Kyaw et al., 2010). The mechanisms
by which B-2 B cells can aggravate atherosclerosis are incom-
pletely understood. Anti-CD20 treatment was associated with an
increase in the percentage of IL-17+ T cells (Th17 cells), and
IL-17A neutralization abrogated anti-CD20 attenuation of ather-
osclerosis (Ait-Oufella et al., 2010). These results imply that IL-17
may mediate B-2 cell aggravation of atherosclerosis (Figure 2).
However, the role for IL-17 in atherosclerosis remains controver-
sial (Erbel et al., 2009; Taleb et al., 2009; van Es et al., 2009; Gao
et al., 2010; Smith et al., 2010; Butcher et al., 2012; Danzaki et al.,
2012). In addition to increasing Th17 cells, anti-CD20 treatment
was also associated with a decrease in CD4 T cell secretion of the
Th1 cytokine IFNγ, and reduced proliferation and activation of
splenic CD4 T cells (Ait-Oufella et al., 2010; Sage et al., 2012). Sev-
eral pro-atherogenic roles for Th1 cells have been identified and
reviewed (Zhou, 2003; Taleb et al., 2010; Dumitriu and Kaski, 2011;
Hansson and Hermansson, 2011; Lahoute et al., 2011; Weber and
Noels, 2011; Campbell et al., 2012). Depletion of B-2 B cells was
also associated with decreased T cells in the atherosclerotic plaque
(Ait-Oufella et al., 2010; Kyaw et al., 2012; Sage et al., 2012), sug-
gesting that B-2 B cells may aggravate atherosclerosis by regulating
T cells in the aorta as well as the spleen.
B-2 B cells may also aggravate atherosclerosis by producing
pathogenic antibodies. B-2 B cell depletion was associated with
a reduction in total serum IgG including IgG1, IgG2a, IgG2c, as
well as IgG1 and IgG2a in the atherosclerotic plaque. Further-
more, B-2 cell depletion resulted in a reduction in serum IgG
against modified lipids, oxLDL and malondialdehyde LDL (MDA-
LDL). Consistent with the predominant depletion of B-2 cells and
not B-1a B cells, there were only modest decreases in total IgM
and IgM against MDA-LDL and oxLDL (Ait-Oufella et al., 2010;
Kyaw et al., 2010, 2012; Sage et al., 2012). Interestingly, univariate
analysis revealed that serum levels of IgG and IgM to oxLDL have
divergent associations with coronary artery disease in humans.
IgM to OxLDL was inversely associated with coronary artery dis-
ease while IgG was positively associated (Tsimikas et al., 2007).
Mechanisms whereby adaptive immunoglobulins might regulate
plaque development are poorly understood. Downstream of anti-
body production, B cells may indirectly regulate atherosclerosis
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in an antigen-independent manner when IgG immune complexes
bind to Fc gamma receptors (FcγR). Activating FcγRs have been
implicated as being pro-atherogenic (Hernandez-Vargas et al.,
2006) and inhibitory FcγRIIb anti-atherogenic (Kelly et al., 2010;
Mendez-Fernandez et al., 2011). Additionally, IgE and its Fc recep-
tor present on mast cells, FcεR1α, are pro-atherogenic (Wang et al.,
2011).
B-2 B cells may also promote atherosclerosis by altering other
inflammatory mediators in the aorta. The loss of BAFFR in
Apoe−/− mice resulted in decreased immunostaining of VCAM1,
CD11c, CD83 and PCNA, and reduced gene expression of the
inflammatory markers TNFα, IL1β, and MCP1 in the atheroscle-
rotic lesion (Kyaw et al., 2012). Presumably, these changes are due
to loss of B-2 cells. Although, other BAFFR-dependent mecha-
nisms may regulate these changes as BAFFR may also be expressed
on T cells (Ye et al., 2004). Many questions about the role of
B-2 cells in atherosclerosis remain. What activates the adaptive
immune system in atherosclerosis? More specifically, what acti-
vates B cells? Do conventional B-2 cells respond to activation and
produce antibodies that directly regulate atherosclerosis in a pro-
tective or pathogenic way? Might atherosclerosis be an allergic
disease (Binder and Witztum, 2011)?
REGULATORY B CELLS IN ATHEROSCLEROSIS
As regulatory B cells produce IL-10 (Madan et al., 2009; Saraiva
and O’Garra, 2010; Mauri and Bosma, 2012), the likely hypothesis
is that they are atheroprotective (Figure 2). Mice null for IL-10
develop significantly more atherosclerosis than controls (Mal-
lat et al., 1999a; Pinderski Oslund et al., 1999). IL-10 has been
reported to protect from atherosclerosis by inhibiting production
of pro-inflammatory mediators and apoptosis, and modulating
lipid metabolism (Mallat et al., 1999a; Von Der Thüsen et al., 2001;
Binder et al., 2003; Caligiuri et al., 2003). Bregs also express fas lig-
and and tumor necrosis factor-related apoptosis-inducing ligand
(Von Der Thüsen et al., 2001; Mauri and Bosma, 2012). These
molecules induce apoptosis in target cells through cell–cell inter-
actions, which may be an important mechanism for suppressing
pro-inflammatory immune responses in atherosclerotic lesions.
Surface markers that define Bregs are poorly understood, making
their function in atherosclerosis hard to study. Indeed, a direct role
for regulatory B cells in atherosclerosis has not yet been reported.
CONTEXT AND TIMING OF B CELL FUNCTION IN
ATHEROSCLEROSIS
The role of B cells in regulating atherosclerosis is likely more
complex than just simple subset distinction. It is likely that exoge-
nous factors impact on B cell subsets to alter their biology. For
example, a newly described population of effector B cells, termed
“innate response activator” (IRA) B cells is derived from peri-
toneal B-1a B cells. Adoptive transfer of B-1a B cells from CD45.2
mice to the peritoneal cavity of LPS-treated CD45.1 mice demon-
strated that B-1a B cells can convert to granulocyte-macrophage
colony-stimulating factor (GM-CSF) producing IRA B cells in the
spleen (Rauch et al., 2012). GM-CSF converts Ly6Clo monocytes
to pathogenic Ly6Chi monocytes in the spleen, which can then
traffic to atherosclerotic lesions and become atherogenic foam
cells, exacerbating atherosclerosis (Zhou, 2003). It is important
to note that these cells change their surface marker expression
from CD19+B220loCD11b±CD5+CD43+ in the peritoneal cav-
ity to CD19+B220hiCD11b−CD5+CD43+ in the spleen (Rauch
et al., 2012), demonstrating environment-dependent B-1a B cell
plasticity with respect to surface marker expression (Tumang et al.,
2004; Steinberg and Witztum, 2010). A direct role for IRA B cells
in atherosclerosis has yet to be determined (Figure 2).
The importance of context is also suggested by data demon-
strating that adoptive transfer of 30× 106 splenic B-2 cells from
Apoe−/− mice attenuated atherosclerosis in B cell deficient µMT
Apoe−/− mice fed 16 weeks of Western diet. Transfer of 60× 106
Apoe−/− splenic B-2 cells had an even greater attenuation of ath-
erosclerosis in µMT Apoe−/− mice (Doran et al., 2012). These
findings are in apparent contrast to the adoptive transfer studies
of Kyaw et al. (transferred 5× 106 splenic B-2 cells from a C57BL/6
mice toµMT Apoe−/−mice) suggesting that the number of B cells
transferred or differences in genotype (Apoe−/− vs. C57BL/6) or
phenotype (hyperlipemic or normolipemic) of the donor mice
may be important (Kyaw et al., 2010; Lipinski et al., 2011). Indeed,
Caligiuri et al. reported a greater attenuation of atherosclerosis
with splenocytes transferred from older atherosclerotic mice com-
pared to C57BL/6J mice or young Apoe−/− mice (Caligiuri et al.,
2002).
In addition, evidence suggests that B cells may have specific
functions in their local environment in the aorta. Doran et al. uti-
lized an Apoe−/− mouse null for Id3 to explore the importance of
vessel wall B cells in atherosclerosis. Id3, a helix loop helix tran-
scription factor, and its partner proteins are important for B cell
development and function (Pan et al., 1999; Engel and Murre,
2001; Murre, 2005). Apoe−/− and Apoe−/− Id3−/−mice contained
an equal number of splenic and circulating B cells, consistent with
prior reports (Pan et al., 1999). However, significantly fewer B cells,
and a marked increase in atherosclerosis, were detected in the aor-
tas of Apoe−/− Id3−/− mice. Similar results have subsequently
been reported in Ldlr−/− mice (Lipinski et al., 2012). Moreover,
in contrast to splenic B cells from wildtype Apoe−/− mice, adop-
tively transferred splenic B cells from Apoe−/− Id3−/−mice did not
home to the aorta of µMT Apoe−/− mice, and subsequent analysis
revealed no difference in atherosclerosis. Interestingly, radiola-
beled splenic B cells from Apoe−/− mice adoptively transferred to
µMT Apoe−/− mice predominantly homed to specific sites within
the aorta suggesting regional preferences for homeostatic B cell
trafficking to the vessel wall. B cells appear to home and reside
in regions prone to atherosclerotic disease (Doran et al., 2012;
Lipinski et al., 2012), and loss of B cells in these locations is associ-
ated with an increase in atherosclerosis development. Notably, the
above studies evaluating immune cell composition of the aorta by
flow cytometry and B cell homing by imaging were performed in
mice prior to the development of atherosclerosis, suggesting that
resident immune cells in the aorta at baseline are important for the
response to atherogenic stimuli (Figure 3). In this context, B cells
were linked to atheroprotection. These B cells may represent the
innate arm of B cell-mediated responses to atherogenic stimuli.
Innate immunity plays a major role in initial defense against
disease by using natural receptors that discriminate “self” vs.
“neo-self” epitopes. In the context of atherosclerosis, self epi-
topes, such as native LDL can become modified after oxidation to
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FIGURE 3 | Immune cells at homeostasis in the adventitia of C57BL/6
andApoe−/− mice. A healthy blood vessel is composed of an endothelial
layer, an intima in between the endothelial layer and smooth muscle cell layer,
and a smooth muscle cell layer (media) surrounded by the adventitia and
peri-vascular fat. (A)The adventitia of a C57BL/6 mouse contains T cells, B
cells, macrophages, dendritic cells, and others (neutrophils, natural killer cells,
and natural killer T cells; Galkina et al., 2006; Jongstra-Bilen et al., 2006). (B)
Apoe−/− mice have an increase in the number of T cells and macrophages,
with a lesser increase in dendritic cells and other cells (neutrophils, natural
killer cells, and natural killer T cells) compared to C57BL/6 (Galkina et al.,
2006). Abundant adventitial B cells persist in the Apoe−/− mouse (Galkina
et al., 2006; Doran et al., 2012). They also have an expanded peri-vascular fat
pad compared to (A). Abbreviation: Mac, macrophage; DC, dendritic cell; EC,
endothelial cell; SMC, smooth muscle cell; Adip, adipocyte.
become neo-self epitopes in the form of MDA-LDL and oxLDL.
Oxidation-specific epitopes are a class of “danger signals,” and are
recognized by pattern recognition receptors in innate immunity,
which include scavenger receptors, innate effector proteins, and
natural IgM antibodies (Binder et al., 2005; Miller et al., 2011). In
addition to oxidized lipids, lipid-laden macrophages that undergo
apoptosis expose the phosphorylcholine (PC) group, a neo-self
epitope, on oxidized phospholipids (oxPL) in their plasma mem-
brane (Miller et al., 2011). One group of antibodies that recognizes
the PC group on oxPLs and apoptotic cells are referred to as
T15 antibodies, which include E06, and are present in athero-
sclerotic plaques (Shaw et al., 2000; Chou et al., 2009). A turning
point in the progression of atherosclerosis is the failure to resolve
inflammation, which usually involves the suppression of cell infil-
tration, effective clearance of apoptotic cells, and promotion of cell
efflux from the arterial wall. However, when there are defects in
these mechanisms, or when these mechanisms are overwhelmed,
atherosclerotic plaques progress to dangerous plaques capable
of rupture (Tabas, 2010). Lipid antigen and apoptotic cells may
overwhelm innate immunity and stimulate the adaptive immune
system, resulting in loss of immune tolerance, and a stimulation
of increased autoantibodies (Miller et al., 2011; Weih et al., 2012).
B cells may have different functions at later stages of athero-
sclerosis. At homeostasis, dendritic cells, macrophages, T cells and
B cells are present in the adventitia and peri-aortic adipose tis-
sue in wildtype and hyperlipidemic mice without atherosclerosis
(Figure 3) (Galkina et al., 2006; Doran et al., 2012), indicating
that the aortic adventitia and surrounding peri-vascular fat is a
homeostatic niche for specific leukocytes including B cells. Most
of these B cells at homeostasis are follicular B cells based on their
surface marker expression (Table 1) with 1–2% B-1 B cells also
being present (our unpublished observations). After 20 weeks of
Western diet-induced atherosclerosis in Apoe−/− mice, the total
number of macrophages, T cells, and dendritic cells, but not B cells,
increase significantly (Galkina et al., 2006). This was associated
with the formation of ATLOs (Figure 1) (Libby, 2012). Without
Western diet, ATLOs and lesions form together at >52 weeks of
age. These ATLOs are found mostly in the abdominal aorta and
less so in the thoracic aorta, consistent with the thoracic aorta
being devoid of lesions at early time points. In advanced athero-
sclerosis, ATLOs contain B cell follicles with germinal centers and
follicular dendritic cell networks. Germinal centers show signs of
activated B cells because they contain proliferating B cells sur-
rounded by follicular mantle cells. Plasma cells are also present
(Grabner et al., 2009). These observations suggest that at this
advanced stage of disease, innate protection may be overwhelmed
and adaptive responses with loss of tolerance may predominate.
The fact that ATLOs are found adjacent to advanced plaques only in
aged mice, has led to the notion that B cells in ATLOs are reactive
and atherogenic (Weih et al., 2012). Taken together, these stud-
ies raise potentially important distinctions between homeostasis,
where B cells may be protective (Doran et al., 2012), and advanced
disease, where lipid antigen and apoptotic cells may overwhelm
protective cells.
B CELLS IN HUMAN ATHEROSCLEROSIS
How findings in murine models will apply to understanding
human atherosclerotic disease pathogenesis or how this may
impact on therapy remains unknown. The advantages of mouse
models of atherosclerosis, such as vast genetic information, afford-
ability, feasible genetic manipulation, and pharmaceutical testing,
makes it a favorable tool for understanding disease pathology.
However, the rate of development, location, and manifestations
of atherosclerotic lesions studied in mice may differ from clini-
cally significant lesions in humans (Schwartz et al., 2007; Zadelaar
et al., 2007; Pendse et al., 2009; Bentzon and Falk, 2010; Getz and
Reardon, 2012). In addition, surface markers that identify B cell
subsets differ between mice and humans. While CD5 is a marker
of B-1a cells in mice, it does not reliably discriminate between B-1
and B-2 cells in humans (Freedman et al., 1989; Sims et al., 2005;
Lee et al., 2009; Griffin et al., 2011; Kaminski et al., 2012). A major
step toward translating questions about the role of B cell subsets
in the context of human atherosclerosis came with the elegant
study by Griffin et al. that identified a circulating human B cell
Frontiers in Immunology | B Cell Biology December 2012 | Volume 3 | Article 373 | 6
Perry et al. B cells in atherosclerosis
subset with functional properties similar to those associated with
murine B-1 cells. Circulating B cells had been reported to produce
IgM antibodies against modified lipids (Chou et al., 2009), but it
was unknown which B cell fraction was responsible. The investi-
gators tested sort-purified B cell fractions for four functions that
typify murine B-1 cells: spontaneous IgM secretion, contain PC-
binding antigen receptors, efficient T cell stimulation, and tonic
intracellular signaling. The human B cell fraction that met these
criteria was CD20+CD27+CD43+ (Griffin et al., 2011). Follow on
studies identified CD11b+CD20+CD27+CD43+ B cells termed
orchestrator B-1 cells that are increased in SLE patients, sponta-
neously produce IL-10, and suppress T cell activation. IL-10 has
been shown to be associated with protective functions in human
atherosclerosis, consistent with mouse data (Uyemura et al., 1996;
Mallat et al., 1999b; Smith et al., 2001; Heeschen et al., 2003;
Fichtlscherer et al., 2004). CD11b− B-1 cells primarily secrete
IgM antibody are termed secretor B-1 cells (Griffin and Roth-
stein, 2011, 2012). Notably, the percentage of circulating human
CD27+ B cells belonging to the B-1 subset declines with age in a
pattern strikingly similar to the inverse of the age-related increase
in atherosclerosis prevalence. Moreover, published studies provide
evidence that circulating levels of IgM that bind modified lipids,
which are inversely associated with coronary artery disease, decline
with age (Tsimikas et al., 2007). Taken together, it is very intrigu-
ing to hypothesize that the circulating human subset identified by
Griffin et al. may play an atheroprotective role in humans.
How to test the hypothesis that human B-1 cells are atheropro-
tective is the challenge. While the promise of translating important
findings in murine models of atherosclerosis to humans concludes
the discussion section of hundreds of important scientific papers,
including those reporting on the role of B cells in atherosclerosis,
the reality is that this translation is rarely realized at this juncture.
This is not for want of such translation, but rather due to signif-
icant practical limitations. The expense and duration of clinical
end-point trials is one such barrier. As such, identification and
utilization of surrogate markers of atherosclerosis-based clinical
events is essential (Choi et al., 2008; Fraley et al., 2009; Weismann
et al., 2011; Purushothaman et al., 2012). Our group is cur-
rently utilizing coronary artery intravascular ultrasound (IVUS) in
humans to quantitate the amount of coronary artery atheroscle-
rotic plaque and determine if associations exist between plaque
burden and the percentage of circulating B cells that belong to
the CD20+CD27+CD43+ subset. Given the age-related decline in
circulating CD20+CD27+CD43+ cells and the multiple covari-
ates linked to atherosclerosis that exist in a human population,
this study will need a large number of subjects and a large amount
of investigator perseverance.
CONCLUDING REMARKS
While a myriad of questions remain unanswered, our understand-
ing of the role played by B cells in murine models of atherosclerosis
has made significant leaps in the last decade. If we are to translate
these important murine findings to humans and unravel the role of
B cells in human atherosclerosis we need to start testing for novel B
cell phenotypes associated with clinical or subclinical atheroscle-
rotic cardiovascular disease. Hopefully, these associations will lead
to new mechanistic hypotheses that can be tested in prospective,
controlled clinical studies.
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